The Efficacy and Safety of Epicutaneous Immunotherapy for Milk Allergy: A Systematic Review

Main Article Content

Laura M. Alvarez-Florian
Waynice N. Paula-Garcia
https://orcid.org/0000-0003-0020-5295
Geovanny Gutierrez
Victor Van Vaisberg
Himadri Vakharia
https://orcid.org/0000-0002-9947-3881
Giulliana M. Moralez
https://orcid.org/0000-0002-3780-4008
Marisa Armeno
https://orcid.org/0000-0002-6776-6380
Gabriela Garcia-Nieto
https://orcid.org/0000-0003-2224-7576
Marcos V. Sangrador-Deitos
https://orcid.org/0000-0003-0770-1830
Chizoma Ndikom
Vikram Ayapati
https://orcid.org/0000-0002-7013-6523
Valentina Contreras
https://orcid.org/0000-0002-9040-3561
Adriana Montalvan
https://orcid.org/0000-0003-1415-5612
Yosra M. El khatem Ahmed Hassan
Ahmed Hassan
Aalia Omer Yousif Mohamedahmed
Raquel Horowitz
https://orcid.org/0000-0002-4909-2925

Abstract

Introduction: Cow’s milk allergy (CMA) is rising among children and adults, affecting 2-3% of children in affluent countries. Currently, the only standard of care is dairy restriction. However, epicutaneous immunotherapy (EPIT) is being studied as a potential treatment involving transdermal administration of an allergen to induce tolerance. EPIT has been proven safe for managing other food allergies in children and adolescents, but its efficacy for CMA is yet to be determined.


Methods: A systematic search of four databases (PubMed, ScienceDirect, SCOPUS, and clinicaltrials.gov) was conducted in September 2022 by three independent reviewers. Additional studies were found by manual reference browsing. All published articles and randomized controlled trials (RCTs) that assessed the effect of EPIT on CMA in children and adolescents aged ≤18 years were included. The search terms used were “epicutaneous immunotherapy” or “immunotherapy” or “EPIT”; “milk allergy” or “cow’s milk allergy” or “CMA” or “CMPA”; “children” or “young” or “kids.”


Results: Six studies were included after a systematic search of 123 studies, with three RCTs evaluating the safety and efficacy of EPIT in children with CMA and three meta-analyses and reviews on EPIT for CMA. The findings were inconclusive but suggested the possibility of treating cow’s milk allergy.


Discussion: EPIT shows promise in treating food allergies, including CMA. Evidence is lacking to determine its efficacy for CMA. More clinical trials with different dosages and longer follow-ups are needed. Results should be interpreted with caution due to limited studies.

Article Details

How to Cite
The Efficacy and Safety of Epicutaneous Immunotherapy for Milk Allergy: A Systematic Review. (2023). Principles and Practice of Clinical Research, 9(1). https://doi.org/10.21801/ppcrj.2023.91.3
Section
View and Review

How to Cite

The Efficacy and Safety of Epicutaneous Immunotherapy for Milk Allergy: A Systematic Review. (2023). Principles and Practice of Clinical Research, 9(1). https://doi.org/10.21801/ppcrj.2023.91.3

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 9 10 11 > >>